Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells

Gene Therapy

Volumn 20, Issue 3, 2013, Pages 308-317

  Liu, Y ^a   Joo, K I ^a   Wang, P ^a,b  

^a University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS TYPE 8 VECTOR; CLATHRIN; PARVOVIRUS VECTOR; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; ENDOCYTOSIS; ENDOSOME; GENE DOSAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; INTRACELLULAR TRANSPORT; MICROTUBULE; PH; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TARGET CELL; TRANS GOLGI NETWORK; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENOME;

BIOLOGICAL TRANSPORT; CELL NUCLEUS; CLATHRIN; CYTOSKELETON; DEPENDOVIRUS; ENDOCYTOSIS; ENDOSOMES; FURIN; GENETIC VECTORS; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, CONFOCAL; MICROTUBULES; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANS-GOLGI NETWORK; TRANSDUCTION, GENETIC; UBIQUITIN;

ADENO-ASSOCIATED VIRUS;

EID: 84874759776     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.41     Document Type: Article

References (58)

1. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Therapy 2008; 15: 858-863.
2. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327.
3. Choi VW, McCarty DM, Samulski RJ. AAV Hybrid serotype: improved vectors for gene delivery. Curr Gene Ther 2006; 5: 299-310.
4. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Therapy 1995; 2: 357-362.
5. Grimm D, Kay M. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
6. Gao G, Wilson J. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297.
7. Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008; 16: 1189-1199.
8. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12: 341-355.
9. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
10. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073-1080.
11. Nakai H, Fuess S, Storm TA. Muramatsu S-i, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
12. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
13. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
14. Summerford C, Samulski R. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
15. Akache B, Grimm D, Pandey K, Stephen R, Yant HX, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80: 9831-9836.
16. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adenoassociated viral vectors. Gene Therapy 2005; 12: 873-880.
17. Hansen J, Qing K, Kwon H, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000; 74: 992-996.
18. Pajusola K, Gruchala M, Joch H, Luscher TF, Yla-Herttuala S, Bueler H. Celltype- specific characteristics modulate the transduction efficiency of adenoassociated virus type 2 and restrain infection of endothelial cells. J Virol 2002; 76: 11530-11540.
19. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74: 2777-2785.
20. Ding W, Zhang LN, Yeaman C, Engelhardt JF. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 2006; 12: 671-682.
21. Joo K-I, Fang Y, Liu Y, Xiao L, Gu Z, Tai A et al. Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano 2011; 5: 3523-3535.
22. Douar A-M. Poulard K, Stockholm D, Danos O. Intracellular trafficking of adenoassociated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824-1833.
23. Hansen J, Qing K, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol 2001; 75: 4080-4090.
24. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsid with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006; 80: 11040-11054.
25. Suikkanen S, Antila M, Jaatinen A, Vihinen-Ranta M, Vuento M. Release of canine parvovirus from endocytic vesicles. Virology 2003; 316: 267-280.
26. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73: 10371- 10376.
27. Seisenberger G, Ried MU, Endre T, Buning H, Hallek M, Brauchle C. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 2001; 294: 1929-1932.
28. Schmid SL. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu Rev Biochem 1997; 66: 511-548.
29. Wang LH, Rothberg KG, Anderson RGW. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993; 123: 1107-1117.
30. Orlandi PA, Fishman PH. Filipin-dependent inhibition of cholera toxin: Evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol 1998; 141: 905-915.
31. Bowman EJ, Siebers A, Altendorf K. Bafilomycins - a class of inhibitors of membrane atpases from microorganisms, animal-cells, and plant-cells. Proc Nat Acad Sci USA 1988; 85: 7972-7976.
32. Stenmark H, Parton R, Steele-Mortimer O, Lutcke A, Gruenberg J, Zerial M. Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J 1994; 13: 1287-1296.
33. Press B, Feng Y, Hoflack B, Wandinger-Ness A. Mutant Rab7 Causes the Accumulation of Cathepsin D and Cation-independent Mannose 6-Phosphate Receptor in an Early Endocytic Compartment. J Cell Biol 1998; 140: 1075-1089.
34. Choudhury A, Dominguez M, Puri V, Sharma DK, Wheatley KNCL, Marks DL et al. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J Clin Invest 2002; 109: 1541-1550.
35. Sanlioglu S, Benson P, Yang J, Atkinson E, Reynolds T, Engelhardt J. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000; 74: 9184-9196.
36. Bantel-Schaal U, Huband B, Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol 2002; 76: 2340-2349.
37. Tsai B. Penetration of nonenveloped viruses into the cytoplasm. Annu Rev Cell Dev Biol 2007; 23: 23-43.
38. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 2005; 79: 1992-2000.
39. Farr GA, Zhang L, Tattersall P. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc Nat Acad Sci USA 2005; 102: 17148-17153.
40. Richards RM, Lowy DR, Schiler JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Nat Acad Sci USA 2006; 103: 1522-1527.
41. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-XArg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 1992; 267: 16396-16402.
42. Liu G, Thomas L, Warren RA, Enns CA, Cunningham CC, Hartwig JH et al. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. J Cell Biol 1997; 139: 1719-1733.
43. Yan Z, Zak R, Luxton GWG, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76: 2043-2053.
44. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587.
45. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5: 121-132.
46. Gruenberg J. The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 2001; 2: 721-730.
47. Mayor S, Presley JF, Maxfield FR. Sorting of membrane components from endosomes and subsequent recycling to the cell surface occurs by a bulk flow process. J Cell Biol 1993; 121: 1257-1269.
48. Mellman I, Warren G. The road taken: past and future foundations of membrane traffic. Cell 2000; 100: 99-112.
49. Watanabe R, Asakura K, Rodriguez M, Pagano R. Internalization and sorting of plasma membrane sphingolipid analogues in differentiating oligodendrocytes. J Neurochem 1999; 73: 1375-1383.
50. Mukherjee S, Soe TT, Maxfield FR. Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J Cell Biol 1999; 144: 1271-1284.
51. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004; 2: 109-122.
52. Girod A, Wobus CE, Zadori Z, Ried M, Leike K, Tijssen P et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002; 83: 973-978.
53. Vihinen-Ranta M, Kalela A, Makinen P, Kakkola L, Marjomaki V, Vuento M. Intracellular route of canine parvovirus entry. J Virol 1998; 72: 802-806.
54. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J 2009; 11: 65-77.
55. Akache B, Grimm D, Shen X, Fuess S, Yant SR, Glazer DS et al. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 2006; 15: 330-339.
56. Auricchio A, Hildinger M, O'Connor E, Gao G, Wilson J. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
57. Conway J, Rhys C, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward G et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Therapy 1999; 6: 986-993.
58. Joo K-I, Tai A, Lee C-L, Wong C, Wang P. Imaging multiple intermediates of single-virus membrane fusion mediated by distinct fusion proteins. Microsc Res Tech 2010; 73: 886-900.